ARCHIVES

“Sloppy” Searle Studies Described By FDA At Kennedy Hearing; Rauscher “Outraged”

This article is from The Cancer Letter archive.

Vol. 02 No. 04 | January 23, 1976

Download PDF Visit The Full Archive

Related Articles

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

April 25, 2014

Double Trouble For NIH: Democrats Offer Small Increases, Bush May Veto The Bill.

July 6, 2007

Carbone Heads Chairmen’s Group

June 30, 1978

Patients Sue Milken, Cancer Centers, Over Prostate Cancer Remedy PC-Spes

February 20, 2004

Calcitrol+Docetaxel Prolongs Survival In Prostate Cancer

June 24, 2005

NCI Supports Development Of Reinoids for Prevention; No Magic Bullet

May 6, 1977